208 related articles for article (PubMed ID: 31569719)
21. Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma.
Hua YP; Yin XY; Peng BG; Li SQ; Lai JM; Liang HZ; Liang LJ
Chemotherapy; 2009; 55(5):312-20. PubMed ID: 19590186
[TBL] [Abstract][Full Text] [Related]
22. Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatment.
Rahmi G; Malka D; Tomasic G; Dromain C; Ducreux M; Boige V
J Clin Oncol; 2007 Jun; 25(16):e15-6. PubMed ID: 17538153
[No Abstract] [Full Text] [Related]
23. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
Montella L; Addeo R; Caraglia M; Faiola V; Guarrasi R; Vincenzi B; Palmeri A; Capasso E; Nocera V; Tarantino L; Ariete M; Martorelli A; Del Prete S
Oncol Rep; 2008 Aug; 20(2):385-90. PubMed ID: 18636202
[TBL] [Abstract][Full Text] [Related]
24. The potential role of somatostatin analogues in breast cancer treatment.
Pollak M
Yale J Biol Med; 1997; 70(5-6):535-9. PubMed ID: 9825480
[TBL] [Abstract][Full Text] [Related]
25. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
Yuen MF; Poon RT; Lai CL; Fan ST; Lo CM; Wong KW; Wong WM; Wong BC
Hepatology; 2002 Sep; 36(3):687-91. PubMed ID: 12198662
[TBL] [Abstract][Full Text] [Related]
26. The significance of somatostatin analogues in the antiproliferative treatment of carcinomas.
Kath R; Höffken K
Recent Results Cancer Res; 2000; 153():23-43. PubMed ID: 10626287
[TBL] [Abstract][Full Text] [Related]
27. Use of tamoxifen in hepatocellular carcinoma: a review and paradigm shift.
Tan CK; Chow PK; Findlay M; Wong C; Machin D
J Gastroenterol Hepatol; 2000 Jul; 15(7):725-9. PubMed ID: 10937676
[TBL] [Abstract][Full Text] [Related]
28. The palliative management of non-islet cell tumour hypoglycaemia with glucocorticoids and somatostatin analogues in an unresectable hepatocellular carcinoma.
North AS; Thakkar RG; James RA; Hammond JS
Ann R Coll Surg Engl; 2022 Jun; 104(6):e180-e182. PubMed ID: 35133207
[TBL] [Abstract][Full Text] [Related]
29. Octreotide therapy for hepatocellular carcinoma: a systematic review of the evidence from randomized controlled trials.
Jia WD; Zhang CH; Xu GL; Ge YS; Wang W
Hepatogastroenterology; 2010; 57(98):292-9. PubMed ID: 20583430
[TBL] [Abstract][Full Text] [Related]
30. The tumour vanishes.
Todd JF; Meeran K
Clin Endocrinol (Oxf); 2000 Dec; 53(6):663-4. PubMed ID: 11155085
[No Abstract] [Full Text] [Related]
31. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo.
Raderer M; Hejna MH; Muller C; Kornek GV; Kurtaran A; Virgolini I; Fiebieger W; Hamilton G; Scheithauer W
Int J Oncol; 2000 Jun; 16(6):1197-201. PubMed ID: 10811995
[TBL] [Abstract][Full Text] [Related]
32. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer.
Dimitroulopoulos D; Xinopoulos D; Tsamakidis K; Zisimopoulos A; Andriotis E; Markidou S; Panagiotakos D; Chrysohoou C; Bazinis A; Paraskevas E
Hepatogastroenterology; 2002; 49(47):1245-50. PubMed ID: 12239914
[TBL] [Abstract][Full Text] [Related]
33. Somatostatin Octapeptide Inhibits Cell Invasion and Metastasis in Hepatocellular Carcinoma Through PEBP1.
Huang CZ; Huang AM; Liu JF; Wang B; Lin KC; Ye YB
Cell Physiol Biochem; 2018; 47(6):2340-2349. PubMed ID: 29990987
[TBL] [Abstract][Full Text] [Related]
34. Treatment of endocrine gastroenteropancreatic tumors with somatostatin analogues.
Fehmann HC; Wulbrand U; Arnold R
Recent Results Cancer Res; 2000; 153():15-22. PubMed ID: 10626286
[TBL] [Abstract][Full Text] [Related]
35. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.
Becker G; Allgaier HP; Olschewski M; Zähringer A; Blum HE;
Hepatology; 2007 Jan; 45(1):9-15. PubMed ID: 17187405
[TBL] [Abstract][Full Text] [Related]
36. [The role of somatostatin analogues in the treatment of hypophyseal adenomas].
Losa M; Mortini P; Giovanelli M
Minerva Endocrinol; 2003 Mar; 28(1):39-51. PubMed ID: 12621362
[TBL] [Abstract][Full Text] [Related]
37. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
38. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses.
de Herder WW; Lamberts SW
Curr Opin Oncol; 2002 Jan; 14(1):53-7. PubMed ID: 11790981
[TBL] [Abstract][Full Text] [Related]
39. Octreotide treatment of hepatocellular carcinoma.
Kouroumalis E; Samonakis D; Skordilis P
Hepatology; 2003 Feb; 37(2):477. PubMed ID: 12540801
[No Abstract] [Full Text] [Related]
40. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.
Aparicio T; Ducreux M; Baudin E; Sabourin JC; De Baere T; Mitry E; Schlumberger M; Rougier P
Eur J Cancer; 2001 May; 37(8):1014-9. PubMed ID: 11334727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
